Physician profile
Eric Ryan Penton
NPI 1942837562
$655.65
in general payments reported to CMS, 2019-2025
13 companies · $192 in 2025
The $192 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $167 · 2024: $297 · 2025: $192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $114.28 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $67.59 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $61.09 | 2023-2024 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $60.65 | 2024-2025 | Cologuard Collection Kit |
| Amgen INC. | $58.53 | 2023-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $58.22 | 2023-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $55.99 | 2023-2024 | Breztri, Airsupra |
| Dexcom, INC. | $50.75 | 2024-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $40.83 | 2024-2025 | Tymlos |
| Pfizer INC. | $29.38 | 2024 | |
| Merck Sharp & Dohme LLC | $22.94 | 2025 | Capvaxive, Gardasil 9 |
| Astellas Pharma US INC | $20.26 | 2023 | Veozah |
| Organon LLC | $15.14 | 2023 | Nuvaring, Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Penton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.